Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease
2019-000824-17Phase 2Terminated
- Sponsor
- Landos Biopharma, Inc.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing BT-11 with Placebo (2 arms). Primary endpoints: Clinical remission at Week 12 and Endoscopic response at Week 12. Started May 2021; status: terminated.
02
Drugs
omilancor
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2019-000824-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000824-17.